Thursday, AbbVie Inc. (ABBV) announced positive results from the Phase 2 PICCOLO trial, which assessed the investigational mirvetuximab soravtansine also known as ELAHERE, as a standalone treatment for heavily treated patients with folate receptor-alpha positive, platinum-sensitive ovarian cancer or PSOC.
The study successfully achieved its primary endpoint with an objective response rate of 51.9%. Additionally, the median duration of response, a significant secondary outcome, was recorded at 8.25 months.
The company stated that Mirvetuximab soravtansine's safety profile aligned with previous study findings, and no new safety issues were detected.
The company plans to unveil complete data from the PICCOLO study at an upcoming medical conference.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.